Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Should l Buy ?
Source: Newsfilter
Patent Grant Announcement: Protagenic Therapeutics, Inc. has received a patent from the Japanese Patent Office for a modified stilbenoid aimed at treating epilepsy and seizures, which will provide exclusivity until March 31, 2041.
Market Insights: The Japanese pharmaceutical market is projected to grow from over $85 billion in 2025 to $93 billion by 2030, while the global epilepsy drug market is expected to increase from $11.29 billion in 2024 to around $18.74 billion by 2034.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
